Colin A. Vale

Colin A. Vale

Hematology

1365 Clifton Road Northeast
BldgC
Atlanta, GA 30322

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 6 publications

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

Journal: Blood

Published: May 04, 2026

(Donor) age is more than just a number….

(Donor) age is more than just a number….

Journal: Bone marrow transplantation

Published: September 05, 2024

SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis.

SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis.

Journal: Clinical lymphoma, myeloma & leukemia

Published: August 13, 2024

Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives.

Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives.

Journal: Cancers

Published: February 17, 2024

Antibiotic use during cytarabine consolidation in acute myeloid leukemia.

Antibiotic use during cytarabine consolidation in acute myeloid leukemia.

Journal: Annals of hematology

Published: June 15, 2020

The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov.

The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov.

Journal: Future oncology (London, England)

Published: July 19, 2018

Showing 1-6 of 6

Last Updated: 09/26/2026